CalliSpheres® microsphere transarterial chemoembolization combined with 125I brachytherapy for patients with non-small-cell lung cancer liver metastases

Guangsheng Zhao; Song Liu; Ying Liu; Xiang Li; Guangji Yu; Yuewei Zhang; Jie Bian; Jianlin Wu; Jun Zhou; Fei Gao

doi:10.3389/fonc.2022.882061

CalliSpheres^® microsphere transarterial chemoembolization combined with ¹²⁵I brachytherapy for patients with non-small-cell lung cancer liver metastases

Front Oncol. 2022 Aug 12:12:882061. doi: 10.3389/fonc.2022.882061. eCollection 2022.

Authors

Guangsheng Zhao¹, Song Liu², Ying Liu³, Xiang Li¹, Guangji Yu², Yuewei Zhang³, Jie Bian⁴, Jianlin Wu⁵, Jun Zhou¹, Fei Gao⁶

Affiliations

¹ Cancer Interventional Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
² Cancer Interventional Center, Linyi Cancer Hospital, Linyi, China.
³ Hepatobiliary and Pancreatic Center, Beijing Tsinghua Changgung Hospital, Beijing, China.
⁴ Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
⁵ Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
⁶ Cancer Interventional Center, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.

Abstract

Objective: Poor prognosis and limited treatments of liver metastases from non-small-cell lung cancer (NSCLC) after radical surgery are critical issues. The current study aimed to evaluate the efficacy and safety of CalliSpheres^® microsphere transarterial chemoembolization (CSM-TACE) plus ¹²⁵I brachytherapy in these patients.

Methods: A total of 23 patients with liver metastases from NSCLC after radical surgery were included. All patients received CSM-TACE 1-3 times, then ¹²⁵I brachytherapy was carried out following the last CSM-TACE. Complete response (CR), objective response rate (ORR), disease control rate (DCR), survival, and adverse events were evaluated.

Results: CR, ORR and DCR were 43.5%, 87.0%, and 100%, respectively, at three months; furthermore, they were 78.3%, 100%, and 100% accordingly at six months. Moreover, most European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) subscales of functions (including physical and emotional function) and symptoms (including pain, nausea, and vomiting) were generally improved at three months (all P < 0.05). Furthermore, median progression-free survival (PFS) was 14.0 [95% confidence interval (CI): 10.4-17.6] months, with a 1-year PFS rate of 62.9%, but the 2-year PFS rate was not reached. Moreover, the median overall survival (OS) was 22.0 (95% CI: 16.8-27.2) months, with a 1-year OS rate of 91.3% and a 2-year OS rate of 43.5%. Additionally, the main adverse events included fever (100%), pain (65.2%), liver function impairment (65.2%), fatigue (56.5%), and nausea and vomiting (52.2%), which were all categorized as grade 1-2.

Conclusion: CSM-TACE plus ¹²⁵I brachytherapy is effective and safe in patients with liver metastases from NSCLC after radical surgery, providing a potentially optimal option in these patients.

Keywords: CalliSpheres® microsphere transarterial chemoembolization plus 125I brachytherapy; adverse events; non–small‐cell lung cancer liver metastases; survival; treatment response.